Eur Rev Med Pharmacol Sci 2022; 26 (14): 5008-5013

DOI: 10.26355/eurrev_202207_29287

Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature

M. De Felice, P. De Marinis, G. Martin, S. Bruscella, A. De Bellis, L. Poliero, G. Turitto

Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy. marco.defelice1993@gmail.com


BACKGROUND: Glioblastoma (GBM) is a highly lethal disease despite integrated treatment comprising radiotherapy plus concomitant and adjuvant temozolomide, with a median overall survival of less than 15 months. For recurrent glioblastoma, there is yet no standard therapy, considering that Bevacizumab have failed to improve overall survival (OS) while regorafenib had a little benefit over standard chemotherapy. In addition, the disease control rate is almost exclusively stability, with a poor objective response rate.

CASE REPORT: Here we present a case of rapid response to regorafenib in early glioblastoma progression at the end of adjuvant radiotherapy: after a single cycle of regorafenib the patient observed an impressive improvement in clinical condition, disappearance of headaches and a clear reduction of neoplastic tissue in MRI. A brief review about new radiological patterns in Magnetic Resonance Imaging (MRI) related to the introduction in clinical practice of antiangiogenic drugs and tyrosine kinase inhibitors has also been carried out.

CONCLUSIONS: Regorafenib was certainly a first turning point in the second-line treatment of GBM, showing longer response rates and mostly disease stability than bevacizumab. A switch-maintenance strategy with tyrosine kinase inhibitors may represent a valid second-line therapeutic option.

Free PDF Download

To cite this article

M. De Felice, P. De Marinis, G. Martin, S. Bruscella, A. De Bellis, L. Poliero, G. Turitto
Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 14
Pages: 5008-5013
DOI: 10.26355/eurrev_202207_29287